Viro-MICST™

Magnetic cell purification and transduction in one integrated system 

i-MICST™ Technology (Integrated Magnetic Immuno-Cell Sorting and Transfection/Transduction) is a new platform that allows to genetically modifying cells (transfection or transduction) directly on magnetic cell purification columns.
This technology combines cell isolation and genetic modification in one simple, efficient and reliable integrated system.

Viro-MICST™ reagent is specially designed for i-MICST Technology.
This reagent is a new magnetic nanoparticles formulation issued from our Magnetofection ™ Technology that allows high transduction efficiency with low Multiplicity of Infection (MOI) during magnetic cell separation.

Viro-MICST™ allows you to reduce cell manipulation steps and save time as well as vector material. This technology is ideal for sensitive cell types such as Primary and Stem Cells.  

• Isolation and transduction of cells in one reliable integrated system

• High and increased transduction efficiency with low MOI

• Rapid, simple and ready to use

• Accelerate the transduction process and synchronize adsorption

• Infect non permissive cells

• Suitable for all viruses and all cells
  

   

How does it work?

i-MICST™ Technology requires:

- Magnetic cell separation systems (not provided by OZ Biosciences)
- Viro-MICST™ reagent for capturing virus and infecting cells within the magnetic cell purification column.

Viro-MICST™was developed in association with MACS^® technology * from Miltenyi Biotec.
Results and demonstration were performed on MS and LS columns with MACS^® separators and the cell separation reagents according to MACS^® cell separation protocol .

*MACS® is a registered trademark owned by Miltenyi Biotec GmbH and the use of MACS® column is proprietary and patented technology. For any further licensed of MACS® system, please contact Miltenyi.    

Rapid, simple and ready-to-use

Learn More about i-MICST™ Technology, see our illustrated protocol .

1. Data 1: High level of target cell transduction during purification  (Fig.1) 
2. Data 2: Viro-MICST™ increases lentiviral transduction efficiency of stem cells (Fig.2)
3. Data 3: Viro-MICST™ increases adenoviral transduction efficiency of stem cells (Fig.3)
4. Data 4: Effect of Viro-MICST™ on cell viability and phenotype (Fig.4/5)

Product listing

High level of target cell transduction during purification

Fig.1: Viro-MICST™ technology increases the transduction efficiency of Primary Blood Mononuclear Cells during purification step onto a modified cell sorting column. Human PBMC (extracted from whole blood) were labeled with either CD45, CD2 or CD15 microbeads then each condition were loaded into: i)      one unmodified LS column, and selected cells were then infected using standard lentiviral protocol with a MOI of 0.5 (standard infection) or ii)     one unmodified LS column followed by a LS column modified with Viro-MICST/ LV. eGFP complexes formulated at a MOI of 0.5 with 6.5 µL of Viro-MICST per 10e6 VP. Infection efficiency was measured by flow cytometry [*].    More results

Various cells infected with the viral i-MICST procedure

Viro-MICST™ increases lentiviral transduction efficiency of stem cells

Fig.2: Viro-MICST™ enhanced stem cells transduction as compared to standard transduction.  1X10e6 hUC-MSC cells were transduced at different MOI using either standard lentiviral transduction procedure or Viro-MICST.  For Viro-MICST, 1x10e6 hUC-MSC cells were labeled with CD105 microbeads and loaded into one Viro-MICST/ LV.eGFP modified LS column (13 µL per 10e6 VP). Transduction efficiency was measured by flow cytometry 3 days post-transduction.[*].        More results

Effect of Viro-MICST™ on cell viability and phenotype

Fig.4: hUC-MSCs maintain their differentiation potential after using Viro-MICST™ procedure. 1X10e6 hUC-MSCs were labeled with CD105 microbeads and loaded into LS columns modified with Viro-MICST/LV.eGFP (10µL/10e6 VP). The cells were stimulated using an osteogenic medium after 48h and analyzed (18 days later) using alizarin red staining. Pictures are bright field microscopy images of the stimulated (differentiated) and non-stimulated hUC-MSCs.                   Fig. 5: No modification of the metabolic activity after Viro-MICST™. Metabolic activity (MTT) of hPBMCs was performed 48 h after lentiviral i-MICST (MOI = 2, different Viro-MICST/VP ratios) or after polybrene infection (Pb) [*].

Sanchez-Antequera Y et al., Blood. 2011; 117(16):e171-81.

Product listing